- €50.72bn
- €58.30bn
- €21.16bn
- 73
- 33
- 56
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.25 | ||
| PEG Ratio (f) | 0.87 | ||
| EPS Growth (f) | 16.44% | ||
| Dividend Yield (f) | 2.02% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.72 | ||
| Price to Tang. Book | 12.42 | ||
| Price to Free Cashflow | 21.11 | ||
| Price to Sales | 2.4 | ||
| EV to EBITDA | 10.72 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.05% | ||
| Return on Equity | 9.95% | ||
| Operating Margin | 17.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 17,534 | 19,687 | 22,232 | 20,993 | 21,156 | 22,025.54 | 22,920.27 | 5.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +29.47 | +56.01 | +19.19 | -13.64 | +1.83 | +20 | +9.47 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
Directors
- Wolfgang Buechele CSU (62)
- Belen Garijo CMG (60)
- Sascha Held VSU (38)
- Marcus Kuhnert CFO (52)
- Kai Beckmann CEX (55)
- Constantin Fest DIR
- Peter Guenter EXB
- Renate Koehler IND (65)
- Peter Merck IND (54)
- Helga Ruebsamen-Schaeff IND (72)
- Daniel Thelen IND (46)
- Simon Thelen IND (41)
- Helene von Roeder IND (51)
- Gabriele Eismann SUB (59)
- Edeltraud Glaenzer SUB (65)
- Juergen Glaser SUB
- Anne Lange SUB (37)
- Dietmar Oeter SUB (54)
- Alexander Putz SUB
- Christian Raabe SUB (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 18th, 1995
- Public Since
- October 20th, 1995
- No. of Employees
- 62,557
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
XETRA- Shares in Issue
- 434,777,878
- Address
- Frankfurter Strasse 250, DARMSTADT, 64293
- Web
- https://www.merckgroup.com/
- Phone
- +49 6151720
- Contact
- Constantin Fest
- Auditors
- Deloitte GmbH Wirtschaftsprufungsgesellschaft
Latest News for MRK
Upcoming Events for MRK
Merck KGaA Annual Shareholders Meeting
Dividend For MRCG.DE - 2.2000 EUR
Dividend For MKKGY.PK - 0.5001 USD
Q1 2025 Merck KGaA Earnings Release
Q1 2025 Merck KGaA Earnings Press Conference
Q1 2025 Merck KGaA Earnings Call
Q2 2025 Merck KGaA Earnings Release
Q2 2025 Merck KGaA Earnings Press Conference
Q2 2025 Merck KGaA Earnings Call
Merck KGaA Capital Markets Day
Similar to MRK
FAQ
As of Today at 22:00 UTC, shares in Merck KGaA are trading at €116.65. This share price information is delayed by 15 minutes.
Shares in Merck KGaA last closed at €116.65 and the price had moved by -20.75% over the past 365 days. In terms of relative price strength the Merck KGaA share price has underperformed the FTSE Global All Cap Index by -22.15% over the past year.
The overall consensus recommendation for Merck KGaA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Merck KGaA dividend yield is 1.89% based on the trailing twelve month period.
Last year, Merck KGaA paid a total dividend of €2.20, and it currently has a trailing dividend yield of 1.89%.Looking ahead, shares in Merck KGaA are due to go ex-dividend on 2025-04-28 and the next dividend pay date is 2025-04-30.
Merck KGaA are due to go ex-dividend on 2025-04-28 and the next dividend pay date is 2025-04-30. The historic dividend yield on Merck KGaA shares is currently 1.89%.
To buy shares in Merck KGaA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €116.65, shares in Merck KGaA had a market capitalisation of €50.72bn.
Here are the trading details for Merck KGaA:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: MRK
Based on an overall assessment of its quality, value and momentum Merck KGaA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Merck KGaA is €177.60. That is 52.25% above the last closing price of €116.65.
Analysts covering Merck KGaA currently have a consensus Earnings Per Share (EPS) forecast of €9.26 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Merck KGaA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -27.35%.
As of the last closing price of €116.65, shares in Merck KGaA were trading -21.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Merck KGaA PE ratio based on its reported earnings over the past 12 months is 12.25. The shares last closed at €116.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Merck KGaA's management team is headed by:
- Wolfgang Buechele - CSU
- Belen Garijo - CMG
- Sascha Held - VSU
- Marcus Kuhnert - CFO
- Kai Beckmann - CEX
- Constantin Fest - DIR
- Peter Guenter - EXB
- Renate Koehler - IND
- Peter Merck - IND
- Helga Ruebsamen-Schaeff - IND
- Daniel Thelen - IND
- Simon Thelen - IND
- Helene von Roeder - IND
- Gabriele Eismann - SUB
- Edeltraud Glaenzer - SUB
- Juergen Glaser - SUB
- Anne Lange - SUB
- Dietmar Oeter - SUB
- Alexander Putz - SUB
- Christian Raabe - SUB